AT
Athira Pharma, Inc.
ATHA · NASDAQ
$6.75 -6.12% (-$0.44)
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Weak
1/9Valuation
-
N/A P/E N/A
EV/FFO N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
-
N/A ROIC N/A
Asset turnover N/A
ROE N/A
Debt
-
N/A Debt/Equity N/A
Debt/Assets N/A
Current ratio N/A
Stability
0 /100
Unstable Beta 2.80x
Rev. volatility N/A
Profitable years N/A
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o ATHA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mark J. Litton
Employees
26
Headquarters
Bothell